As HCC44 cells show a P53 mutation and a high c-MYC expression [27] which is also maintained under 3D conditions (Figure S5), we tested the AURKA inhibitor alisertib, which is reported to induce c-MYC degradation in P53 mutant cancer [83]. The gene discussed is TP53; the disease is cancer.